The content on this site is intended for healthcare professionals only
Dr Vulfovich speaks with ecancertv at the Best of ASCO 2016 about novel treatments for ovarian cancer.
Using BRCA mutations as a marker, he describes the significance of PARP inhibitor treatment on survival.
For the initial announcement of results from olaparib in ovarian cancer, you can watch an interview with Dr Jonathan Ledermann here.
ESMO 2024: Optimising the personalisation of prostate cancer treatment
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Choosing Wisely in pathology
Choosing Wisely in radiology Tanzania
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC
Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
